TITLE

Levodopa/benserazide

PUB. DATE
April 2014
SOURCE
Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p26
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a case study of a 35-year-old woman with dyskinesias which developed during treatment with levodopa, followed by levodopa/benserazide for dystonia.
ACCESSION #
95660643

 

Related Articles

  • Amantadine/levodopa.  // Reactions Weekly;1/29/2011, Issue 1336, p6 

    The article describes the case of a 14-year-old girl who developed peak-dose dyskinesias while undergoing levodopa therapy for juvenile Parkinsonism.

  • Levodopa.  // Reactions Weekly;4/13/2013, Issue 1448, p22 

    The article presents a case study of two men who developed peak-dose levodopa-induced dyskinesias (LID) and on-off phenomena while being treated with levodopa.

  • Levodopa.  // Reactions Weekly;9/29/2012, Issue 1421, p35 

    The article describes the clinical cases of four patients, diagnosed with multiple system atrophy (MSA), who developed dyskinesias while under levodopa treatment regimen.

  • Levodopa/carbidopa.  // Reactions Weekly;10/29/2011, Issue 1375, p19 

    The article describes the case of an elderly woman diagnosed with Parkinson's disease (PD), who developed respiratory and limb/trunk dyskinesias while under levodopa/carbidopa treatment regimen.

  • Clinical Aspects and Management of Levodopa-Induced Dyskinesia. Tambasco, Nicola; Simoni, Simone; Marsili, Erica; Sacchini, Elisa; Murasecco, Donatella; Cardaioli, Gabriela; Rossi, Aroldo; Calabresi, Paolo // Parkinson's Disease (20420080);2012, p1 

    In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias. Strategies to delay or to reduce dyskinesias are based on the change of levodopa...

  • Levodopa/carbidopa: Dyskinesia: case report.  // Reactions Weekly;6/22/2019, Vol. 1758 Issue 1, p217 

    No abstract available.

  • L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Pearce, R. K. B.; Heikkilä, M.; Lindén, I.-B.; Jenner, P. // Psychopharmacology;2001, Vol. 156 Issue 4, p402 

    Rationale: L-Dopa induces dyskinesias during the treatment of Parkinson's disease and also in primates with nigrostriatal lesions produced by MPTP, but it is claimed that L-dopa does not provoke dyskinesia in humans or monkeys with an intact or mildly damaged nigrostriatal system. Objectives:...

  • Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. Gravius, Andreas; Dekundy, Andrzej; Nagel, Jens; Morè, Lorenzo; Pietraszek, Małgorzata; Danysz, Wojciech // Journal of Neural Transmission;Dec2008, Vol. 115 Issue 12, p1609 

    In the present study, we evaluated the effects of subchronic blockade of mGluR5 by 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) on learning, anxiety and levodopa-induced dyskinesia in rats. In addition, we excluded the possibility that subchronic treatment produced pharmacokinetic...

  • Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic? Lane, Emma; Dunnett, Stephen // Psychopharmacology;Aug2008, Vol. 199 Issue 3, p303 

    Several different animal models are currently used to research the neurodegenerative movement disorder Parkinson’s disease (PD). Models based on the genetic deficits associated with a small percentage of sufferers demonstrate the pathological accumulation of α-synuclein characteristic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics